The Technical Analyst
Innoviva Inc [INVA]
Exchange: Nasdaq Global Select Sector: Healthcare Industry: Biotechnology
Innoviva Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
0.91% $14.44
Last updated: 7 aug 2022 - 23:21
TimeZone: America/New_York
FIND ALL MARKETS
FIND ALL STOCKS LISTED @ NASDAQ Live Signal Oslo
Live Signal Nasdaq
Live Signal Crypto
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 1 006.55 mill |
| EPS: | 1.390 |
| P/E: | 10.39 |
| Earnings Date: | Oct 25, 2022 |
| SharesOutstanding: | 69.71 mill |
| Avg Daily Volume: | 0.882 mill |
| RATING 2022-08-05 |
|---|
| A+ |
| Strong Buy |
| RATINGDETAILS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Neutral | |
| Return On Asset: | Neutral | |
| DE: | Buy | |
| P/E: | Strong Buy | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 1/21 | 2/21 | 3/21 | 4/21 | 1/22 | 2/22 | |
| Revenue | ||||||
| Gr.Profit | n/a | n/a | n/a | n/a | ||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.02x |
| Company: PE 10.39 | sector: PE 480.39 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| infx |
| Company: PE 10.39 | industry: PE 0.000 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$16.43 (13.77%) $1.989 |
| Date: 2022-08-08 |
| Expected Trading Range (DAY) |
|---|
|
$ 13.97 - 14.91 ( +/- 3.28%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2022-05-20 | Zhen Marianne | Sell | 828 | Common Stock |
| 2022-05-13 | Zhen Marianne | Buy | 1 834 | Common Stock |
| 2022-05-02 | Raifeld Pavel | Buy | 150 000 | Nonstatutory Stock Option |
| 2022-04-25 | Birx Deborah | Buy | 10 000 | Non-statutory Stock Option |
| 2022-04-25 | Birx Deborah | Buy | 12 647 | Common Stock |
| INSIDER POWER |
|---|
| -84.58 |
| Last 100 transactions |
| Buy: 1 180 882 | Sell: 32 174 096 |
Forecast:
16:00 - $14.44
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $14.44
Forecast 2: 16:00 - $14.44
Forecast 3: 16:00 - $14.44
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $14.44 (0.91% ) |
| Volume | 0.677 mill |
| Avg. Vol. | 0.882 mill |
| % of Avg. Vol | 76.75 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For INVA
69 Signals | Accuracy: 21.74% | Accuracy Buy: 26.47% | Accuracy Sell: 17.14%
Avg return buy: -0.17 % | Avg return sell: 0.11 %
$1 invested is now $0.94 or -5.72% since 25-07-22
| Date | Signal | @ | Closed | % | Aug 5 - 15:28 | buy | $14.39 | N/A | Active |
|---|---|---|---|---|
| Aug 5 - 14:18 | sell | $14.40 | $14.39 @ Aug 5 - 15:28 | -0.10% |
| Aug 5 - 13:48 | buy | $14.42 | $14.40 @ Aug 5 - 14:18 | -0.14% |
| Aug 5 - 13:31 | sell | $14.37 | $14.42 @ Aug 5 - 13:48 | 0.35% |
| Aug 5 - 11:51 | buy | $14.34 | $14.37 @ Aug 5 - 13:31 | 0.24% |
| Aug 5 - 11:30 | sell | $14.26 | $14.34 @ Aug 5 - 11:51 | 0.53% |
| Aug 5 - 10:35 | buy | $14.24 | $14.26 @ Aug 5 - 11:30 | 0.14% |
| Aug 5 - 10:31 | sell | $14.22 | $14.24 @ Aug 5 - 10:35 | 0.14% |
| Aug 5 - 10:17 | buy | $14.23 | $14.22 @ Aug 5 - 10:31 | -0.07% |
| Aug 5 - 10:01 | sell | $14.22 | $14.23 @ Aug 5 - 10:17 | 0.07% |
INVA
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
Latest Press Releases
2022-07-13 16:32:00 - Press Release
Innoviva Sells 15% Economic Stake In Theravance Respiratory Company To Royalty Pharma For Approximately $282 Million Plus Full Ownership Of Existing Equity Investments And The Potential For $50 Million Milestone Payment
Burlingame, calif.--(business wire)--innoviva, inc. (nasdaq: inva) (“innoviva”), a diversified holding company with a portfolio of royalties and a growing portfolio of innovative healthcare assets, today announced that the company has entered into an agreement to sell its 15% economic stake in theravance respiratory company llc (“trc”), which receives royalties stemming from sales of trelegy® ellipta®, to royalty pharma plc (nasdaq: rprx) for an upfront cash payment of approximately $282 millio
2022-07-12 09:37:00 - Press Release
Shareholder Alert: Rigrodsky Law, P.a. Is Investigating La Jolla Pharmaceuticals Company Buyout
Wilmington, delaware--(newsfile corp. - july 12, 2022) - rigrodsky law, p.a. is investigating la jolla pharmaceuticals company ("la jolla") (nasdaq: ljpc) regarding possible breaches of fiduciary duties and other violations of law related to la jolla's agreement to be acquired by innoviva inc. (nasdaq: inva). under the terms of the agreement, la jolla's shareholders will receive $6.23 in cash for each share of la jolla common stock they own.to learn more about this investigation...
2022-07-11 23:44:00 - Press Release
Shareholder Alert: Weiss Law Investigates La Jolla Pharmaceutical Company
New york , july 11, 2022 /prnewswire/ -- weiss law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of la jolla pharmaceutical company ("la jolla" or the "company") (nasdaq: ljpc) in connection with the proposed acquisition of the company by innoviva, inc. (nasdaq: inva) via tender offer. under the terms of the merger agreement, the company's shareholders will receive $6.23 in cash for each share of la jolla common stock owned.
2022-07-11 20:34:00 - Press Release
La Jolla Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, Llc Investigates Adequacy Of Price And Process In Proposed Sale Of La Jolla Pharmaceutical Company - Ljpc
New orleans--(business wire)--former attorney general of louisiana charles c. foti, jr., esq. and the law firm of kahn swick & foti, llc (“ksf”) are investigating the proposed sale of la jolla pharmaceutical company (nasdaqcm: ljpc) to innoviva, inc. (nasdaqgs: inva). under the terms of the proposed transaction, shareholders of la jolla will receive only $6.23 in cash for each share of la jolla that they own. ksf is seeking to determine whether this consideration and the process that led to
2022-07-11 09:17:00 - Press Release
Innoviva Completes Acquisition Of Entasis Therapeutics
Burlingame, calif.--(business wire)--innoviva, inc. (nasdaq: inva) (“innoviva”), a diversified holding company with a portfolio of royalties, today announced the successful completion of its acquisition of entasis therapeutics holdings inc. (“entasis”), an advanced late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products. entasis brings to innoviva an exciting portfolio that includes potentially first- and best-in-class medicines for
Latest News
2022-07-13 17:41:01 - Benzinga
Theravance Biopharma, Innoviva Gain On Selling TRELEGY ELLIPTA Royalty Interests
Theravance Biopharma, Inc. (NASDAQ: TBPH) has agreed to sell all of its units in Theravance Respiratory Company, LLC, representing 85% economic interest in the sales-based royalty rights on worldwide net sales of GSK plc's (NYSE: GSK) TRELEGY ELLIPTA to Royalty.
2022-07-11 11:15:14 - InvestorPlace
La Jolla Pharmaceutical (LJPC) Stock Skyrockets on Innoviva Acquisition News
A headline-grabbing takeover deal could be impactful for the medical community - and today, it's definitely huge news for LJPC stock holders. The post La Jolla Pharmaceutical (LJPC) Stock Skyrockets on Innoviva Acquisition News appeared first on InvestorPlace.
2022-07-11 08:17:02 - Benzinga
Innoviva Bolsters Its Infectious Disease, Hospital Portfolio With La Jolla Deal
Innoviva Inc (NASDAQ: INVA) has agreed to acquire La Jolla Pharmaceutical Company (NASDAQ: LJPC) for $5.95 per share, representing a premium of approximately 70% to the 30-day volume-weighted average price. Innoviva will also pay an incremental $0.28 per share for additional.
2022-05-23 10:17:08 - Benzinga
Innoviva Acquires AstraZeneca-Spin Off At $2.20/Share
Innoviva Inc (NASDAQ: INVA) has agreed to acquire Entasis Therapeutics Holdings Inc (NASDAQ: ETTX) at $2.20 per share in cash. Innoviva currently owns approximately 60% of the outstanding shares of Entasis common stock.
2022-04-20 16:34:20 - Zacks Investment Research
Earnings Preview: Innoviva (INVA) Q1 Earnings Expected to Decline
Innoviva (INVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
2022-04-06 09:47:03 - Zacks Investment Research
Bet on These 4 Low-Beta Stocks to Combat Market Volatility
It is imperative to build a portfolio of low-beta stocks to sail through a choppy market. Meridian (VIVO), Innoviva (INVA), OP Bancorp (OPBK) and United Fire Group (UFCS) are well poised to gain.
2022-04-01 11:07:19 - Zacks Investment Research
Is Innoviva (INVA) Outperforming Other Medical Stocks This Year?
Here is how Innoviva (INVA) and McKesson (MCK) have performed compared to their sector so far this year.
2022-03-05 11:23:00 - The Motley Fool
1 Healthcare Stock That Could Fly Higher After a Strong Q4
This pharmaceutical company is growing revenue and profits from drugs it doesn't market or sell.
2022-03-04 09:14:08 - Zacks Investment Research
Sail Through the Choppy Market With These 4 Low-Beta Stocks
It is imperative to build a portfolio of low-beta stocks to sail through a choppy market. Meridian (VIVO), Innoviva (INVA), Horace (HMN) and Maravai LifeSciences (MRVI) are well poised to gain.
2022-02-24 13:53:14 - Zacks Investment Research
Can Innoviva (INVA) Run Higher on Rising Earnings Estimates?
Innoviva (INVA) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.